Biotech News
Biotechnology
To date, 2025 has been the most active year for LifeArc Ventures. 2 February 2026
Biotechnology
US genomics specialist Illumina has completed its acquisition of proteomics company SomaLogic, adding large-scale protein analysis to its multiomics portfolio and strengthening its push beyond sequencing into faster drug discovery and biomedical research. 2 February 2026
Biotechnology
Resolve M Therapeutics has exited stealth, pitching a discovery platform designed to engage “pro-resolution” immune responses that could help restore immune balance in chronic inflammatory and autoimmune disorders, without broad immunosuppression. 2 February 2026
Most Read
Recent news
Biotechnology
Swiss pharma giant Novartis on Friday revealed it has broken ground on a new, state-of-the-art global Biomedical Research center in San Diego, California, USA, designed to provide world-class scientific infrastructure and drug-discovery capabilities to advance the company’s pipeline for patients. 7 February 2026
Biotechnology
Chinese biotech Kelun-Biotech has won a new approval from China’s National Medical Products Administration for sac-TMT (sacituzumab tirumotecan), a TROP2-directed antibody-drug conjugate. 6 February 2026
Biotechnology
Pfizer today announced that the US Food and Drug Administration (FDA) has accepted and granted Priority Review for the company’s supplemental Biologics License Application (sBLA) for Hympavzi (marstacimab) to expand the approved indication to include the treatment of hemophilia A or B patients 6 years and older with inhibitors, and pediatric patients (ages 6 to 11) with hemophilia A or B without inhibitors. 6 February 2026
Biotechnology
US biotech company Biogen today reported fourth quarter 2025 results topping the market’s revenue expectations, but sales fell by 7.1% year on year to $2.28 billion. Biogen’s share were up 4.3% at $192.97 in early trading. 6 February 2026
Biotechnology
Swiss biotech firm Idorsia today announced the design of its US Food and Drug Administration (FDA)-agreed Phase III registration program for lucerastat in Fabry disease. 6 February 2026
Refine search
In Brief
Biotechnology
2 February 2026 French pharma major Sanofi has breached the Association of the British Pharmaceutical Industry (ABPI) Code of Practice for the Pharmaceutical Industry and brought discredit upon, and reduced confidence in, the pharmaceutical industry.
Biotechnology
26 January 2026 Genethon, a non-profit gene therapy R&D organization founded by the French Muscular Dystrophy Association (AFM-Telethon), began the new year with an R&D licensing deal for its gene therapy approach to Pompe disease and continues pivotal clinical trials of its best-in-class low dose micro-dystrophin gene therapy (GNT0004) for Duchenne muscular dystrophy (DMD).
Insights
Biotechnology
During Blood Cancer Awareness Month, Guy Martin, news editor at The Pharma Letter, sat down with Dr Hanbali to discuss his experiences treating patients with CAR T-cell therapy in the Middle East. 8 December 2025
Biotechnology
Chinese biotech companies are pivoting from "fast-follow" to "smart" first-in-class (FIC) innovation, a shift that is reshaping global licensing deals and driving multinational corporations (MNCs) to integrate more deeply with China’s R&D ecosystem. 26 November 2025
Biotechnology
In a strategic push to transform India’s pharmaceutical and biotech landscape, the government recently outlined and invited applications for the Promotion of Research and Innovation in Pharma MedTech Sector (PRIP) scheme, aimed at bolstering R&D capabilities, particularly in rare disease therapies, gene-based treatments, and precision medicine. 10 November 2025
Biotechnology
Sickle cell disease (SCD) is a group of inherited blood disorders characterised by a single point mutation in the β-globin gene, producing abnormal haemoglobin (Hb) called HbS. This leads to red blood cells (RBCs) deforming into a sickle shape, causing chronic hemolytic anemia, vaso-occlusive crises (VOCs), organ damage and, in severe cases, premature death.1-3 4 November 2025
Biotechnology
Germany-based Immatics has this month announced updated clinical data from its PRAME-directed TCR T-cell therapy, anzu-cel (anzutresgene autoleucel, IMA203), in 16 patients with metastatic uveal melanoma. 3 November 2025
Biotechnology
Russian drugmaker Pharmasyntez and China's Hualan Bio will join forces on the development of new drugs and technology transfer, according to the partners, The Pharma Letter’s local correspondent reports. 22 October 2025
Biotechnology
Pharma has always lived with one eye on the clock. Blockbusters that once defined company fortunes eventually face the reckoning of lost exclusivity, when generics and biosimilars swoop in and cash flows collapse. 25 September 2025
Boardroom
Privately-held San Diego biotech ADARx Pharmaceuticals announced the appointment of Dr Donald Fong as chief medical officer (CMO) to lead the advancement of its clinical-stage pipeline. 6 February 2026
California-based Braveheart Bio, a biotech developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and related cardiovascular conditions, has announced that Marc Evanchik has been promoted to chief scientific officer (CSO). 5 February 2026
UK biotech Levicept, which is focused on the development of LEVI-04, a first-in-class treatment for osteoarthritis (OA), today announced the appointment of James Sandy as chief development officer (CDO). 4 February 2026
Cambridge, UK-based biotech Bicycle Therapeutics, which is pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today announced leadership transitions for its next phase of innovation. 3 February 2026
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze